Dissemin is shutting down on January 1st, 2025

Published in

BMJ Publishing Group, Postgraduate Medical Journal, 1153(97), p. 730-737, 2021

DOI: 10.1136/postgradmedj-2020-138938

Links

Tools

Export citation

Search in Google Scholar

Guidelines for mono, double and triple antithrombotic therapy

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Guidelines for antithrombotic therapy are complex, especially if a patient has several indications that require antithrombotic therapy. In general, no patient should receive lifelong double or triple antithrombotic therapy. In this overview, we outline the most common indications for mono, double and triple antithrombotic therapy; the preferred antithrombotic therapy and the recommended duration of therapy. Both antiplatelet therapy and therapeutic anticoagulation therapy with vitamin K antagonists or direct oral anticoagulants were included. European guidelines were used or, if no European guidelines were available, the Dutch guidelines were used.